LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Elenco Azioni・Cytokinetics Inc

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

78.17 -0.38

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

77.46

Massimo

78.93

Metriche Chiave
By Trading Economics
Entrata	-23M -206M
Vendite	1.6M 19M
EPS	-1.67
Margine di Profitto	-1,064.485
Dipendenti	673
EBITDA	112K -180M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+26.31% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2B 10B
Apertura precedente	78.55
Chiusura precedente	78.17

Notizie sul Sentiment di mercato

By Acuity

50%

148 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

32.3 / 40.43 Supporto e resistenza

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mag 2026, 16:49 UTC

Utili

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mag 2026, 16:26 UTC

I principali Market Mover

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mag 2026, 23:51 UTC

Discorsi di Mercato

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mag 2026, 23:37 UTC

Utili

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

21 mag 2026, 23:30 UTC

Discorsi di Mercato

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mag 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mag 2026, 21:53 UTC

Utili

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mag 2026, 21:02 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mag 2026, 20:55 UTC

Utili

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mag 2026, 20:30 UTC

Azioni calde

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 mag 2026, 20:20 UTC

Discorsi di Mercato

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Adj EPS 3c >BULL

21 mag 2026, 20:20 UTC

Utili

Webull 1Q Rev $159.9M >BULL

21 mag 2026, 20:18 UTC

Discorsi di Mercato

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mag 2026, 20:18 UTC

Utili

Webull 1Q Loss/Shr 4c

21 mag 2026, 19:43 UTC

Discorsi di Mercato

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mag 2026, 18:58 UTC

Utili

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mag 2026, 18:15 UTC

Discorsi di Mercato

Gold Higher For Second Consecutive Day -- Market Talk

21 mag 2026, 17:40 UTC

Discorsi di Mercato

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mag 2026, 17:04 UTC

Discorsi di Mercato

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mag 2026, 17:01 UTC

Utili

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Stellantis Targets Distant but Constructive -- Market Talk

21 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

26.31% in crescita

Previsioni per 12 mesi

Media 98.6 USD 26.31%

Alto 140 USD

Basso 67 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Cytokinetics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

32.3 / 40.43Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

148 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.